Skip to content

LSD: all studies

Page 42 of 282: studies 411 to 420 of 2,815, newest first. Back to the LSD overview

Research

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects

Clinical Pharmacokinetics February 14, 2017 Patrick C. Dolder, Yasmin Schmid, Andrea E. Steuer et al. 134 citations

BACKGROUND AND OBJECTIVE: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure-response relationship of oral LSD. METHODS: We analyzed pharmacokinetic data from two published placebo-controlled, double-blind, cross-over studies using oral administration of LSD 100 and 200 µg in 24 and...

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.

Current Biology February 6, 2017 Katrin H. Preller, Marcus Herdener, Thomas Pokorny et al.

A core aspect of the human self is the attribution of personal relevance to everyday stimuli enabling us to experience our environment as meaningful [1]. However, abnormalities in the attribution of personal relevance to sensory experiences are also critical features of many psychiatric disorders [2, 3]. Despite their clinical relevance, the neurochemical and anatomical substrates enabling...

Crystal structure of an LSD-bound human serotonin receptor

Cell January 26, 2017 Daniel Wacker, Sheng Wang, John D. Mccorvy et al. 466 citations

SUMMARY The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal structure of LSD in complex with the human serotonin receptor 5-HT2B. The complex reveals conformational rearrangements to accommodate LSD, providing a structural explanation for the conformational selectivity of LSD’s key diethylamide moiety. LSD dissociates exceptionally slowly from both...

Possible role of biochemiluminescent photons for lysergic acid diethylamide (LSD)-induced phosphenes and visual hallucinations.

Reviews in the Neurosciences January 1, 2017 Gábor Kapócs, Felix Scholkmann, Vahid Salari et al.

Today, there is an increased interest in research on lysergic acid diethylamide (LSD) because it may offer new opportunities in psychotherapy under controlled settings. The more we know about how a drug works in the brain, the more opportunities there will be to exploit it in medicine. Here, based on our previously published papers and investigations, we suggest that LSD-induced visual...

The pharmacology of d-Lysergic acid diethylamide (LSD)

edoc (University of Basel) 2017 Patrick C. Dolder 1 citation

My PhD thesis consisted of two different scientific parts, each supervised by one of my advisors, Prof. Dr. med. Matthias Liechti and Prof. Dr. sc. nat. Katharina Rentsch. One part was to develop liquid chromatography tandem mass spectrometry (LC-MS/MS) methods to measure d-lysergic acid diethylamide (LSD) and its main metabolites in plasma, serum, and urine samples. We established the...

d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology

International Journal of Molecular Sciences November 23, 2016 Danilo de Gregorio, Stefano Comai, Luca Posa et al. 125 citations

d-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles’...

The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors.

Pharmacological Research November 2016 Danilo de Gregorio, Luca Posa, Rafael Ochoa-Sanchez et al.

d-lysergic diethylamide (LSD) is a hallucinogenic drug that interacts with the serotonin (5-HT) system binding to 5-HT1 and 5-HT2 receptors. Little is known about its potential interactions with the dopamine (DA) neurons of the ventral tegmental area (VTA). Using in-vivo electrophysiology in male adult rats, we evaluated the effects of cumulative doses of LSD on VTA DA neuronal activity,...

DOI: 10.1016/j.phrs.2016.08.022 (opens in new tab) Full text (opens in new tab) Serotonin 8-oh-dpat pubchem cid Apomorphine pubchem cid Dopamine +6

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Psychopharmacology October 7, 2016 Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid 203 citations

Mystical-type experiences were infrequent after LSD, possibly because of the set and setting used in the present study. LSD may produce greater or different alterations of consciousness at 200 μg (i.e., a dose that is currently used in psychotherapy in Switzerland) compared with 100 μg (i.e., a dose used in imaging studies). Ego dissolution may reflect plasma levels of LSD, whereas more...

Rehabilitating LSD history in postwar America: Dilworth Wayne Woolley and the serotonin hypothesis of mental illness

History of Science September 1, 2016 Kim Hewitt 2 citations

Revisiting the history of postwar LSD (lysergic acid diethylamide) research illuminates how the work of a chemist at the Rockefeller Institute contributed to the development of a biochemical paradigm for mental functioning. Dilworth Wayne Woolley proposed one of the first theories of the biochemistry of mental illness based on empirical evidence. His research with LSD and serotonin had...